RhoGAM® Brand Dosing

The dosing instructions for RhoGAM® Brand are clearly defined to ensure that patients are protected from Rh sensitization for the duration of pregnancy. RhoGAM® Brand dosing is aligned with the standards of both the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Blood Banks (AABB).

Precise Dosing Instructions


  • RhoGAM® 300 µg—For antenatal and postpartum use, second- and third-trimester pregnancy terminations, or transplacental hemorrhage1-3
  • MICRhoGAM® 50 µg—For use immediately after first-trimester pregnancy termination 3,4


  • At 28 weeks’ gestation5-8
  • Within 72 hours postpartum1
  • Following spontaneous or induced termination4
  • Following any event that could lead to transplacental hemorrhage (such as amniocentesis, chorionic villus sampling (CVS), percutaneous umbilical blood sampling (PUBS), or abdominal trauma)2


  • RhoGAM® Brand should be administered in 12-week intervals9

Severe systemic allergic reactions are extremely rare.3


  1. RhoGAM® Ultra-Filtered PLUS Package Insert. Ortho Clinical Diagnostics.
  2. RhoGAM® Ultra-Filtered Marketing Authorization Application: Part IB1. Summary of Product Characteristics. Ortho Clinical Diagnostics. November 2000.
  3. Pollack W, Ascari WQ, Kochesky RJ, et al. Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion. 1971;11:333-339.
  4. Frigolette FD Jr, ed. Antepartum administration of Rh immune globulin: a guide to office procedure. Raritan, NJ: Ortho-Diagnostic Systems, Inc. 1983.
  5. Bowman JM, Chown B, Lewis M, et al. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J. 1978;118:623-627.
  6. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks’ gestation service program. Can Med Assoc J. 1978;118:627-630.
  7. Baskett TF, Parsons ML. Prevention of Rh(D) alloimmunization: a cost-benefit analysis. Can Med Assoc J. 1990;142;337-339.
  8. Bowman JM. Antenatal suppression of Rh alloimmunization. Clin Obstet Gynecol. 1991;34:296-303.
  9. Mintz PD. Rh Immune Globulin. In: Mintz PD, ed. Transfusion Therapy: Clinical Principles and Practice, 2nd Edition. Bethesda, MD: AABB Press; 2005.
  10. Freda VJ, Gorman JG, Pollack W, et al. Prevention of Rh hemolytic disease—ten years’ clinical experience with Rh immune globulin. N Engl J Med. 1975;292:1014-1016.
  11. Prevention of Rh D Alloimmunization. ACOG Practice Bulletin. Number 4, May 1999. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists.

Important Safety Information

RhoGAM® Brand is indicated for the prevention of Rh immunization, including during and after pregnancy and other obstetrical conditions or incompatible transfusion of Rh-positive blood.

RhoGAM® and MICRhoGAM® Ultra-Filtered PLUS Rho(D) Immune Globulin (Human) are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent.

RhoGAM® and MICRhoGAM® are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.

RhoGAM® and MICRhoGAM® contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Patients who receive RhoGAM® and MICRhoGAM® for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.

Click here for the RhoGAM® Brand Full Prescribing Information